Targeted Therapy of Hepatitis C

Product description

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-α administered is dependent on the type used.

The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life. Among the first wave of targeted HCV therapeutics are the NS3a protease and NS5B RNA polymerase inhibitors with 25 different compounds in clinical development and further 8 in the IND enabling study phase. Development of HCV protease inhibitors is slightly ahead of polymerase inhibitors. The first study combining HCV protease and polymerase inhibitors was successfully completed.

At least 17 further distinct molecules are in early clinical development and another five close to enter clinical investigation which have novel mechanisms of action. Among the targets are cyclophilin inhibitors, NS5A protein inhibitors, NS4B-RNA binding inhibitors, viral entry and replication inhibitors. Specific therapeutic vaccines and antibodies are included in those novel targeted HCV treatment modalities. Other novel mechanism of action agents are directed against host cell or viral structures.

The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.
  

Index

• HCV Protease Inhibitors
• HCV RNA Polymerase Inhibitors
• Cyclophilin Inhibitors
• HCV NS5A Protein Inhibitors
• HCV NS4B-RNA Binding Inhibitors
• Therapeutic HCV Vaccines
• Therapeutic HCV Antibodies
• HCV Viral Entry Inhibitors
• HCV Replication Inhibitors
• Novel Mechanism of Action HCV Virus Targets
• Novel Mechanism of Action HCV Host Cell Targets
• Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
• About La Merie
  

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.